JP2015531396A5 - - Google Patents

Download PDF

Info

Publication number
JP2015531396A5
JP2015531396A5 JP2015535741A JP2015535741A JP2015531396A5 JP 2015531396 A5 JP2015531396 A5 JP 2015531396A5 JP 2015535741 A JP2015535741 A JP 2015535741A JP 2015535741 A JP2015535741 A JP 2015535741A JP 2015531396 A5 JP2015531396 A5 JP 2015531396A5
Authority
JP
Japan
Prior art keywords
monoclonal antibody
antibody
subject
mabp1
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015535741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015531396A (ja
JP6750941B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/062899 external-priority patent/WO2014055541A1/en
Publication of JP2015531396A publication Critical patent/JP2015531396A/ja
Publication of JP2015531396A5 publication Critical patent/JP2015531396A5/ja
Application granted granted Critical
Publication of JP6750941B2 publication Critical patent/JP6750941B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015535741A 2012-10-04 2013-10-01 精神障害の治療 Active JP6750941B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261709741P 2012-10-04 2012-10-04
US61/709,741 2012-10-04
PCT/US2013/062899 WO2014055541A1 (en) 2012-10-04 2013-10-01 Treatment of psychiatric conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020090717A Division JP2020143133A (ja) 2012-10-04 2020-05-25 精神障害の治療

Publications (3)

Publication Number Publication Date
JP2015531396A JP2015531396A (ja) 2015-11-02
JP2015531396A5 true JP2015531396A5 (https=) 2016-11-17
JP6750941B2 JP6750941B2 (ja) 2020-09-02

Family

ID=50435375

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015535741A Active JP6750941B2 (ja) 2012-10-04 2013-10-01 精神障害の治療
JP2020090717A Pending JP2020143133A (ja) 2012-10-04 2020-05-25 精神障害の治療
JP2022144756A Withdrawn JP2022177132A (ja) 2012-10-04 2022-09-12 精神障害の治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2020090717A Pending JP2020143133A (ja) 2012-10-04 2020-05-25 精神障害の治療
JP2022144756A Withdrawn JP2022177132A (ja) 2012-10-04 2022-09-12 精神障害の治療

Country Status (7)

Country Link
EP (1) EP2903643A4 (https=)
JP (3) JP6750941B2 (https=)
KR (1) KR20150064091A (https=)
CN (1) CN104684581A (https=)
AU (1) AU2013327498B2 (https=)
CA (1) CA2886757C (https=)
WO (1) WO2014055541A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102167261B1 (ko) 2010-06-18 2020-10-20 엑스바이오테크, 인크. 관절염 치료
US10294296B2 (en) 2010-08-23 2019-05-21 Xbiotech, Inc. Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
ES2695102T3 (es) 2011-09-23 2019-01-02 Xbiotech Inc Tratamiento para la caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
CA3053231A1 (en) * 2017-02-16 2018-08-23 Xbiotech Inc. Treatment of hidradenitis suppurativa
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
WO2024095677A1 (ja) 2022-11-04 2024-05-10 パナソニック インテレクチュアル プロパティ コーポレーション オブ アメリカ 端末、基地局、通信方法及び集積回路

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9405021D0 (en) * 1994-03-15 1994-04-27 Unilever Plc Skin treatment composition
US5455234A (en) * 1994-03-16 1995-10-03 Ahluwalia; Gurpreet S. Inhibition of hair growth
JP2002226457A (ja) * 2001-02-02 2002-08-14 Ajinomoto Co Inc 新規シスチン誘導体及び炎症因子活性化抑制剤
CA2726345C (en) * 2008-05-30 2018-08-28 John Simard Interleukin-1 alpha antibodies and methods of use
SG172855A1 (en) * 2009-01-29 2011-08-29 Abbott Lab Il-1 binding proteins
US9724409B2 (en) * 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
JP6062918B2 (ja) * 2011-04-01 2017-01-18 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 皮膚科的病理の治療

Similar Documents

Publication Publication Date Title
JP2015531396A5 (https=)
JP2014509662A5 (https=)
UA118441C2 (uk) Антитіло, що розпізнає альфа-синуклеїн
IL240179A0 (en) Use of a chimeric human monoclonal antibody that binds to il-5r in the production of a drug to reduce the number of basophils in a person's blood
IN2014DN07149A (https=)
JP2015530399A5 (https=)
UA109633C2 (uk) Антитіло людини проти тканинного фактора
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
MY184154A (en) Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
HUE043355T2 (hu) LIV-1 elleni humanizált antitestek és alkalmazásuk a rák kezelésében
IL236664B (en) Monoclonal antibodies for use in diagnosis and therapy of cancers and autoimmune disease
IL212633A (en) A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs
HUE043540T2 (hu) Szubsztituált dimer kinazolin-származék, elõállítása, valamint alkalmazása 1-es és 2-es típusú cukorbetegség kezelésére szolgáló gyógyászati készítményekben
JP2014111603A5 (https=)
MX2019014658A (es) Anticuerpos humanizados que reconocen la alfa-sinucleina.
LT2013015A (lt) Farmacinės kompozicijos
BR112013002167A2 (pt) anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação
IL226957B (en) Human monoclonal antibody with specificity for dengue virus serotype 1 e protein and uses thereof
MX356808B (es) Uso de una composición farmacéutica que comprende un anticuerpo anti-il-1a para el tratamiento de la caquexia.
JP2014526559A5 (https=)
JP2015531397A5 (https=)
JP2015524816A5 (https=)
EP2703488A4 (en) COMPOSITION TO PREDICT SENSITIVITY TO TRASTUZUMAB THERAPY IN BREAST CANCER PATIENTS AND METHODS THEREFOR
IL210204A (en) Ligand, method for preparing it, antibody and pharmaceutical composition comprising same and use thereof in the manufacture of a medicament for treating msrv-associated disease